Wendy Lane

2.7k total citations · 1 hit paper
36 papers, 1.3k citations indexed

About

Wendy Lane is a scholar working on Endocrinology, Diabetes and Metabolism, Surgery and Molecular Biology. According to data from OpenAlex, Wendy Lane has authored 36 papers receiving a total of 1.3k indexed citations (citations by other indexed papers that have themselves been cited), including 33 papers in Endocrinology, Diabetes and Metabolism, 13 papers in Surgery and 9 papers in Molecular Biology. Recurrent topics in Wendy Lane's work include Diabetes Management and Research (32 papers), Diabetes Treatment and Management (28 papers) and Pancreatic function and diabetes (13 papers). Wendy Lane is often cited by papers focused on Diabetes Management and Research (32 papers), Diabetes Treatment and Management (28 papers) and Pancreatic function and diabetes (13 papers). Wendy Lane collaborates with scholars based in United States, Denmark and Canada. Wendy Lane's co-authors include Bruce W. Bode, Timothy S. Bailey, Irl B. Hirsch, Satish K. Garg, Anne L. Peters, Julio Rosenstock, Yehuda Handelsman, Athena Philis‐Tsimikas, Jerzy W. Kolaczynski and Peter Hu and has published in prestigious journals such as The Lancet, JAMA and Diabetes Care.

In The Last Decade

Wendy Lane

32 papers receiving 1.2k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Switching to once-weekly insulin icodec versus once-daily insulin glargine U100 in individuals with basal-bolus insulin-treated type 2 diabetes (ONWARDS 4): a phase 3a, randomised, open-label, multicentre, treat-to-target, non-inferiority trial

2023 86 citations Chantal Mathieu, Björg Ásbjörnsdóttir et al. The Lancet profile →

Peers

Countries citing papers authored by Wendy Lane

Since Specialization

Citations

This map shows the geographic impact of Wendy Lane's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Wendy Lane with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Wendy Lane more than expected).

Fields of papers citing papers by Wendy Lane

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Wendy Lane. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Wendy Lane. The network helps show where Wendy Lane may publish in the future.

Co-authorship network of co-authors of Wendy Lane

This figure shows the co-authorship network connecting the top 25 collaborators of Wendy Lane. A scholar is included among the top collaborators of Wendy Lane based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Wendy Lane. Wendy Lane is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	Switching to once-weekly insulin icodec versus once-daily insulin glargine U100 in individuals with basal-bolus insulin-treated type 2 diabetes (ONWARDS 4): a phase 3a, randomised, open-label, multicentre, treat-to-target, non-inferiority trial breakdown → 2023 ·The Lancet ·Chantal Mathieu, Björg Ásbjörnsdóttir, Harpreet S. Bajaj, Wendy Lane, (unknown), Sreenivasa Murthy, (unknown), Julio Rosenstock	86
2	Effective Overall Glycaemic Control with Fast-Acting Insulin Aspart Across Patients with Different Baseline Characteristics: A Post Hoc Analysis of the Onset 9 Trial 2022 ·Diabetes Therapy ·Wendy Lane, Elena Favaro, Esteban Jódar, (unknown), (unknown), (unknown), Peter Senior, Giorgio Sesti, Edward Franek	1
3	Glycaemic Control in People with Diabetes Starting Treatment with Fast-Acting Insulin Aspart: a US Database Study 2021 ·Diabetes Therapy ·Wendy Lane, Mads Faurby, Lise Lotte N. Husemoen, (unknown), Naveen Rathor, Christophe De Block	3
4	Basal Insulin Degludec and Glycemic Control Compared to Aspart Via Insulin Pump in Type 1 Diabetes (BIGLEAP): A Single-Center, Open-Label, Randomized, Crossover Trial 2021 ·Endocrine Practice ·Wendy Lane, (unknown), (unknown), Benjamin C. Lane, (unknown)	2
5	Glucose Variability and Time in Range in Type 2 Diabetes Treated with U-500R by Pump or Injection: CGM Findings from the VIVID Study 2020 ·Diabetes Technology & Therapeutics ·Thomas Blevins, Wendy Lane, David Rodbard, Dana K. Sindelar, Ludi Fan, (unknown), Liza L. Ilag, Trang T. Ly, Jennal Johnson	8
6	Sotagliflozin in Combination With Optimized Insulin Therapy in Adults With Type 1 Diabetes: The North American inTandem1 Study 2018 ·Diabetes Care ·John B. Buse, Satish K. Garg, Julio Rosenstock, Timothy S. Bailey, Phillip Banks, Bruce W. Bode, Thomas Danne, Jake A. Kushner, Wendy Lane, Pablo Lapuerta, Darren K. McGuire, Anne L. Peters, John H. Reed, Sangeeta Sawhney, Paul Strumph	172
7	A randomized, multicentre trial evaluating the efficacy and safety of fast‐acting insulin aspart in continuous subcutaneous insulin infusion in adults with type 1 diabetes (onset 5) 2018 ·Diabetes Obesity and Metabolism ·David C. Klonoff, Mark L. Evans, Wendy Lane, Hans‐Peter Kempe, Éric Renard, J. Hans DeVries, Tina Graungaard, (unknown), (unknown), Tadej Battelino	57
8	Target Fasting Plasma Glucose (FPG) without Nocturnal Hypoglycemia in Patients with Type 1 Diabetes or Type 2 Diabetes—Results from SWITCH Trials 2018 ·Diabetes ·Carol Wysham, Wendy Lane, Steen Ladelund, (unknown), Simon Heller	0
9	Day-to-day Variability of Fasting Self-Measured Blood Glucose (SMBG) Associates with Hypoglycemia Risk in Adults with Type 1 (T1D) or Type 2 Diabetes (T2D) 2017 ·Canadian Journal of Diabetes ·Timothy S. Bailey, Anuj Bhargava, J. Hans DeVries, (unknown), Janusz Gumprecht, Wendy Lane, Carol Wysham, (unknown), (unknown), Keval Chandarana, Athena Philis‐Tsimikas	0
10	Consensus Statement by the American Association of Clinical Endocrinologists/American College of Endocrinology Insulin Pump Management Task Force 2014 ·Endocrine Practice ·George Grunberger, Jill M. Abelseth, Timothy S. Bailey, Bruce W. Bode, Yehuda Handelsman, Richard Hellman, Lois Jovanovič, Wendy Lane, Philip Raskin, William V. Tamborlane, (unknown)	129
11	The effect of addition of liraglutide to high‐dose intensive insulin therapy: a randomized prospective trial 2014 ·Diabetes Obesity and Metabolism ·Wendy Lane, (unknown), (unknown), (unknown)	65
12	Reduced Risk of Hypoglycemia with Insulin Degludec Versus Insulin Glargine in Patients with Type 2 Diabetes Requiring High Doses of Basal Insulin: A Meta-Analysis of 5 Randomized Begin Trials 2013 ·Endocrine Practice ·Helena W. Rodbard, Stephen Gough, Wendy Lane, Lars Korsholm, Ditte‐Marie Bretler, Yehuda Handelsman	39
13	Reduced Risk of Hypoglycemia with Insulin Degludec vs Insulin Glargine in Patients with Type 2 Diabetes Requiring High Doses of Basal Insulin: Meta-Analysis of Five Randomized Trials 2012 ·Canadian Journal of Diabetes ·Helena W. Rodbard, Yehuda Handelsman, Stephen Gough, (unknown), (unknown), Wendy Lane	5
14	The Effect of Long-Term Use of U-500 Insulin Via Continuous Subcutaneous Infusion on Durability of Glycemic Control and Weight in Obese, Insulin-Resistant Patients with Type 2 Diabetes 2012 ·Endocrine Practice ·Wendy Lane, (unknown), (unknown), (unknown), (unknown), (unknown)	20
15	The Effect of Liraglutide Added to U-500 Insulin in Patients with Type 2 Diabetes and High Insulin Requirements 2011 ·Diabetes Technology & Therapeutics ·Wendy Lane, (unknown), (unknown)	49
16	A Prospective Trial of U500 Insulin Delivered by Omnipod in Patients With Type 2 Diabetes Mellitus and Severe Insulin Resistance 2010 ·Endocrine Practice ·Wendy Lane, (unknown), (unknown), (unknown)	37
17	High-dose Insulin Therapy: is it Time for U-500 Insulin? 2009 ·Endocrine Practice ·Wendy Lane, Elaine Cochran, Jeffrey A. Jackson, Jamie Scism‐Bacon, (unknown), Irl B. Hirsch, Jay S. Skyler	94
18	Screening for harsh punishment in a pediatric primary care clinic 2009 ·Child Abuse & Neglect ·Susan Feigelman, Howard Dubowitz, Wendy Lane, (unknown), Walter Meyer, J. Kathleen Tracy, Jeongeun Kim	23
19	Use of U-500 Regular Insulin by Continuous Subcutaneous Insulin Infusion in Patients with Type 2 Diabetes and Severe Insulin Resistance 2006 ·Endocrine Practice ·Wendy Lane	40
20	Use of the Continuous Glucose Monitoring System to Guide Therapy in Patients With Insulin-Treated Diabetes: A Randomized Controlled Trial 2004 ·Mayo Clinic Proceedings ·Robert J. Tanenberg, Bruce W. Bode, Wendy Lane, Claresa Levetan, Jorge H. Mestman, Anne L. Peters, Janet Tobian, Todd M. Gross, John J. Mastrototaro	103

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact